Anti-CD20 monoclonal antibody used for B-cell depletion to reduce humoral alloimmunity.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby reducing humoral alloimmunity.
Anti-CD20 antibody binds CD20 on B cells and kills via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (via FcγR effector cells), and apoptosis signaling.
Investigational antibody–drug conjugate (ADC) comprising a tumor-targeting antibody linked to a cytotoxic payload; binds a tumor cell-surface antigen, is internalized, and releases an intracellular toxin to kill antigen-expressing HER2-negative breast cancer cells. Target antigen and payload not specified.
Anti-TROP-2 IgG1 antibody-drug conjugate linked via a cleavable linker to the exatecan-derived topoisomerase I inhibitor SHR9265. After binding TROP-2 on tumor cells and internalization, the payload is released to inhibit topoisomerase I, blocking DNA replication and inducing DNA damage–mediated cell cycle arrest and apoptosis in TROP-2–expressing (e.g., HER2-negative) breast cancer cells.
An anti-TROP-2 antibody-drug conjugate binds TROP-2, is internalized, the cleavable linker is processed, and the exatecan-derived topoisomerase I inhibitor (SHR9265) is released inside the cell, inhibiting topo I and causing DNA damage, replication arrest, and apoptosis of TROP-2-expressing cells.
An afucosylated humanized IgG1 monoclonal antibody targeting BCMA (TNFRSF17) on malignant plasma cells; mediates Fcγ receptor–dependent ADCC and ADCP and may induce apoptosis.
Afucosylated humanized IgG1 antibody that binds BCMA on malignant plasma cells; enhanced Fcγ receptor engagement drives NK cell–mediated ADCC and macrophage-mediated ADCP, and may also induce direct apoptosis of target cells.
Afucosylated anti-BCMA IgG1 opsonizes BCMA+ cells and engages Fcγ receptors on NK cells and macrophages to mediate ADCC and ADCP; may also trigger apoptosis via BCMA ligation.
An anti-BCMA antibody–drug conjugate linking belantamab to the cytotoxic payload MMAF; after BCMA-mediated internalization, MMAF disrupts microtubules causing cell death, and the antibody retains Fc-mediated ADCC/ADCP.
Belantamab mafodotin is an anti-BCMA antibody–drug conjugate that binds BCMA on malignant plasma cells, is internalized, and releases the MMAF payload to inhibit microtubules and induce cell death; the afucosylated IgG1 antibody also engages Fc receptors to promote ADCC and ADCP.
Belantamab mafodotin binds BCMA, is internalized, and releases the MMAF payload to disrupt microtubules and kill the cell; its afucosylated IgG also engages Fc receptors to mediate ADCC/ADCP.
Subcutaneous bispecific T‑cell–engaging antibody that binds CD3 on T cells and CD20 on B cells to form an immune synapse, activate TCR/CD3 signaling, and induce T‑cell–mediated cytotoxicity; used here with step‑up dosing around CAR‑T.
Subcutaneous bispecific antibody that binds CD3 on T cells and CD20 on B cells, bringing them into proximity to form an immune synapse, activate TCR/CD3 signaling, and trigger T‑cell–mediated cytotoxicity (perforin/granzyme) against CD20+ B‑cell malignancies.
Epcoritamab bridges CD3+ T cells to CD20+ cells, forming an immune synapse that activates TCR/CD3 signaling and induces perforin/granzyme-mediated T‑cell cytotoxicity against CD20-expressing cells.